A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Phase of Trial: Phase I/II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Panobinostat (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 05 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Jul 2015 according to ClinicalTrials.gov record.
- 05 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jul 2015 according to clinicalTrials.gov record.